Lethal Prion Protein Causes Neuronal Death
|
By LabMedica International staff writers Posted on 01 Mar 2012 |
A single prion protein that is at least 10 times more lethal than larger prion species has been identified that causes disease similar to mad cow disease.
The toxic form of abnormal prion protein, known as TPrP, triggered various forms of neuronal damage, including molecular signatures very similar to that seen in the brains of prion-infected animal with bovine spongiform encephalopathy (BSE).
Scientists at the Scripps Research Institute (Jupiter, FL, USA) found that the most lethal form of prion protein was a specific structure known as alpha-helical. This toxic single molecule or "monomer" tests the existing theory that neuronal damage is associated with the toxicity of prion protein aggregates called "oligomers."
A variety of techniques was used to provide fresh insights into prion diseases, such as BSE and a rare human form Creutzfeldt-Jakob disease. Furthermore, it opened the possibility that associated neurotoxic proteins may play a role in neurodegenerative disorders, such as Parkinson, and Alzheimer's diseases.
In prion disease, proteinaceous infectious particles (infectious prions), believed to be made up only of protein, are able to reproduce, even though they lack ribonucleic acid (RNA) and DNA. Usually, mammalian cells generate cellular prion protein (PrP), when infected with a prion disease; the abnormal protein converts the normal host prion protein into its disease form.
Corinne Lasmézas, PhD, the lead author and a professor at Scripps, said "By identifying a single molecule as the most toxic species of prion proteins, we've opened a new chapter in understanding how prion-induced neurodegeneration occurs. We didn't think we would find neuronal death from this toxic monomer so close to what normally happens in the disease state. Now we have a powerful tool to explore the mechanisms of neurodegeneration."
Professor Lasmézas added, "Until now, it was thought that oligomers of proteins are toxic in all these disease. Since we found for the first time that an abnormally folded monomer is highly toxic, it opens up the possibility that this might be true also for some other protein misfolding diseases as well." The study was published on February 7, 2012 in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Scripps Research Institute
The toxic form of abnormal prion protein, known as TPrP, triggered various forms of neuronal damage, including molecular signatures very similar to that seen in the brains of prion-infected animal with bovine spongiform encephalopathy (BSE).
Scientists at the Scripps Research Institute (Jupiter, FL, USA) found that the most lethal form of prion protein was a specific structure known as alpha-helical. This toxic single molecule or "monomer" tests the existing theory that neuronal damage is associated with the toxicity of prion protein aggregates called "oligomers."
A variety of techniques was used to provide fresh insights into prion diseases, such as BSE and a rare human form Creutzfeldt-Jakob disease. Furthermore, it opened the possibility that associated neurotoxic proteins may play a role in neurodegenerative disorders, such as Parkinson, and Alzheimer's diseases.
In prion disease, proteinaceous infectious particles (infectious prions), believed to be made up only of protein, are able to reproduce, even though they lack ribonucleic acid (RNA) and DNA. Usually, mammalian cells generate cellular prion protein (PrP), when infected with a prion disease; the abnormal protein converts the normal host prion protein into its disease form.
Corinne Lasmézas, PhD, the lead author and a professor at Scripps, said "By identifying a single molecule as the most toxic species of prion proteins, we've opened a new chapter in understanding how prion-induced neurodegeneration occurs. We didn't think we would find neuronal death from this toxic monomer so close to what normally happens in the disease state. Now we have a powerful tool to explore the mechanisms of neurodegeneration."
Professor Lasmézas added, "Until now, it was thought that oligomers of proteins are toxic in all these disease. Since we found for the first time that an abnormally folded monomer is highly toxic, it opens up the possibility that this might be true also for some other protein misfolding diseases as well." The study was published on February 7, 2012 in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
Scripps Research Institute
Latest Microbiology News
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
- High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
- Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
- New Rapid Ebola Antigen Test Detects Infection at Point of Care
- Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
- Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
- Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
- Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Channels
Clinical Chemistry
view channel
Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury
Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more
Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read moreMolecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







